T Cell Nrf2/Keap1 Gene Editing Using CRISPR/Cas9 and Experimental Kidney Ischemia-Reperfusion Injury
Antioxidants & Redox Signaling · 2023
DOI: 10.1089/ars.2022.0058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants & Redox Signaling, 2023. Verfasst von Johanna T Kurzhagen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antioxidants, Reperfusion Injury. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Aims
T cells play pathophysiologic roles in kidney ischemia-reperfusion injury (IRI), and the nuclear factor erythroid 2-related factor 2/kelch-like ECH-associated protein 1 (Nrf2/Keap1) pathway regulates T cell responses. We hypothesized that clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)-mediated Keap1 -knockout (KO) augments Nrf2 antioxidant potential of CD4+ T cells, and that Keap1 -KO CD4+ T cell immunotherapy protects from kidney IRI.
Results
CD4+ T cell Keap1 -KO resulted in significant increase of Nrf2 target genes NAD(P)H quinone dehydrogenase 1, heme oxygenase 1, glutamate-cysteine ligase catalytic subunit, and glutamate-cysteine ligase modifier subunit. Keap1 -KO cells displayed no signs of exhaustion, and had significantly lower levels of interleukin 2 (IL2) and IL6 in normoxic conditions, but increased interferon gamma in hypoxic conditions in vitro . In vivo , adoptive transfer of Keap1 -KO CD4+ T cells before IRI improved kidney function in T cell-deficient nu/nu mice compared with mice receiving unedited control CD4+ T cells. Keap1 -KO CD4+ T cells isolated from recipient kidneys 24 h post IR were less activated compared with unedited CD4+ T cells, isolated from control kidneys. Innovation: Editing Nrf2/Keap1 pathway in murine T cells using CRISPR/Cas9 is an innovative and promising immunotherapy approach for kidney IRI and possibly other solid organ IRI.
Conclusion
CRISPR/Cas9-mediated Keap1 -KO increased Nrf2-regulated antioxidant gene expression in murine CD4+ T cells, modified responses to in vitro hypoxia and in vivo kidney IRI. Gene editing targeting the Nrf2/Keap1 pathway in T cells is a promising approach for immune-mediated kidney diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pediatrics, University of Illinois, Chicago, Illinois, USA.
- Department of Pathology, and University of Illinois, Chicago, Illinois, USA.
- University of Illinois Cancer Center, University of Illinois, Chicago, Illinois, USA.
ORCID-Profile: Johanna T Kurzhagen
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Kurzhagen, J. T., Noel, S., Lee, K., Sadasivam, M., Gharaie, S., Ankireddy, A., Lee, S. A., Newman-Rivera, A., Gong, J., Arend, L. J., Hamad, A. R. A., Reddy, S. P., & Rabb, H. (2023). T Cell Nrf2/Keap1 Gene Editing Using CRISPR/Cas9 and Experimental Kidney Ischemia-Reperfusion Injury. Antioxidants & Redox Signaling. https://doi.org/10.1089/ars.2022.0058
Vancouver
Kurzhagen JT, Noel S, Lee K, Sadasivam M, Gharaie S, Ankireddy A, et al. T Cell Nrf2/Keap1 Gene Editing Using CRISPR/Cas9 and Experimental Kidney Ischemia-Reperfusion Injury. Antioxidants & Redox Signaling. 2023. doi:10.1089/ars.2022.0058
BibTeX
@article{Kurzhagen2023,
author = {Kurzhagen, Johanna T and Noel, Sanjeev and Lee, Kyungho and Sadasivam, Mohanraj and Gharaie, Sepideh and Ankireddy, Aparna and Lee, Sul A and Newman-Rivera, Andrea and Gong, Jing and Arend, Lois J and Hamad, Abdel R A and Reddy, Sekhar P and Rabb, Hamid},
title = {T Cell Nrf2/Keap1 Gene Editing Using CRISPR/Cas9 and Experimental Kidney Ischemia-Reperfusion Injury},
journal = {Antioxidants & Redox Signaling},
year = {2023},
doi = {10.1089/ars.2022.0058}
}
EUVIMED